The Directors take pleasure in presenting the THIRTY FIRST (31st) Annual Reports along with the financial statements for the year ended 31st March, 2023.
FINANCIAL HIGHLIGHTS
|
(Rs. in Million)
|
|
Particulars
|
2022-23
|
2021-22
|
|
Turnover
|
6,552.04
|
6,582.89
|
|
Profit before Depreciation & Amortization expenses, Non-recurring expenses and Tax expenses
|
1,487.72
|
1,521.71
|
|
Less: Depreciation & Amortization Expenses
|
167.37
|
176.63
|
|
Non-recurring expenses
|
-
|
-
|
|
Tax expenses
|
291.69
|
305.20
|
|
Profit after Tax
|
1,028.66
|
1,039.88
|
OPERATIONS/STATE OF AFFAIRS OF THE COMPANY
During the year 2022-23, your Company achieved turnover of H 6,552.04 Million with net profit of H 1,028.66 Million as compared to turnover of H 6,582.89 Million with net profit of H 1,039.88 Million in the previous year.
On consolidated basis, your Company achieved turnover of H 18,521.39 Million with net profit of H 2,653.21 Million as compared to turnover of H 14,908.39 Million with net profit of H 1,868.14 Million in the previous year. During the year, US and North America Formulation business reported growth of 22%, Europe and UK formulation business reported growth of 26%. Australia and New Zealand formulation business reported growth of 16.5% and Rest of World formulation business reported growth of 50.2%.
In compliance with the Ind AS on Consolidated Financial Statements, this Annual Report also includes Consolidated Financial Statements for the financial year under review.
DIVIDEND
The Board of Directors at its Meeting held on 30th May, 2023, declared dividend of H 0.50/- (50%) per equity share of H 1/- each for the financial year ended 31st March, 2023. Total cash outflow on account of dividend payment has been H 226.58 Million for the financial year ended 31st March, 2023. The Dividend has been paid in compliance with applicable regulations and in accordance with Company’s Dividend Distribution policy. The Dividend Distribution policy is available on the Company’s website http:// www.marksanspharma.com/pdf/dividend-distribution-policy.pdf
SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES
i. Marksans Pharma (UK) Limited, through step down subsidiaries Bell, Sons & Co. (Druggists) Limited and Relonchem Limited which operates in the European markets, has achieved sales of H 7,660.99 Million as compared to sales of H 6,075.84 Million during previous year.
ii. Marksans Pharma Inc., through step down subsidiary Time-Cap Laboratories Inc. which operates mainly in US and North America, has achieved sales of H 7,613.03 Million as compared to sales of H 6,288.02 Million during previous year.
iii. Nova Pharmaceuticals Australasia Pty Ltd. (your company holds 60% of the share capital) which operates mainly in Australia and New Zealand has achieved sales of H 1,926.86 Million as compared to sales of H 1,681.22 Million during previous year.
iv. Access Healthcare for Medical Products L.L.C, a wholly owned subsidiary which operates mainly in UAE and neighboring countries has achieved sales of H 218.48 Million.
Pursuant to a Central Government’s Circular dated 8th February, 2011, the audited accounts together with Directors’ Report and Auditors’ Report of the subsidiaries namely Marksans Pharma (U.K.) Limited, Marksans Pharma Inc. and Nova Pharmaceuticals Australasia Pty Limited are not being appended to the Annual Report. However, a statement giving information in aggregate for each subsidiary including step down subsidiaries are attached to the Consolidated Balance Sheet. Statement containing the salient features of financial statements of subsidiary companies and their contribution to the overall performance of the company is annexed to this report as Annexure - I.
Your Company has no Joint Ventures and Associate Companies.
MANAGEMENT DISCUSSION AND ANALYSIS
A report on Management Discussion and Analysis covering industry structure and developments, financial and operational performance of the Company, risks, concerns, opportunities, threats and outlook forms a part of this Report.
RESERVES
Your Company has not transferred any amount out of the profit of the year to the General Reserve.
SHARE CAPITAL
During the year under review, Company has undertaken buyback of equity shares through stock exchange mechanism. The Company bought back & extinguished 64,74,276 equity shares which reduced the paid-up capital of the Company to 40,28,39,422 equity shares by 18th January, 2023.
Further, pursuant to exercise of conversion rights associated with warrants by the warrants-holders and balance consideration having been paid toward subscription money in compliance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the Board of Directors of the Company, at its meeting held on 20th January, 2023, issued and allotted 10,00,000 equity shares to Mr. Mark Saldanha and 4,93,24,324 equity shares to OrbiMed Asia IV Mauritius FVCI Limited at a price of H 74/- per equity share having face value of H 1/- each on preferential basis against the conversion of warrants allotted to them. Accordingly, the paid-up equity share capital of the Company has increased to 45,31,63,746 equity shares with effect from 20th January, 2023.
The Company has neither issued any equity shares with differential rights as to dividend, voting or otherwise nor issued ESOP or sweat equity shares to Directors or employees, under any Scheme.
ACQUISITION OF MANUFACTURING FACILITIES IN GOA
On October 11, 2022, your company entered into a Business Transfer Agreement with Tevapharm India Private Limited to acquire its business relating to the manufacture and supply of pharmaceutical formulations in Plot No. A1, Phase 1-A, Verna Industrial Estate, Verna, Goa - 403722 as a going concern on a slump sale basis. Eventually, your company formally took over the above business in April 2023.
The acquisition has potential to significantly expand your Company’s manufacturing capability and accelerate core growth strategy. It will supplement innovative product portfolio. It is also a testament to the Company’s commitment to invest in product innovation, expand capacities, and drive market share gains. We are confident that this acquisition will lead to a transformational growth journey unlocking further value for the Company’s shareholders.
The above acquisition was for H 77.94 crore and your Company plans to further invest H 200 Crore in next Two years to build an additional capacity of 8 billion units per annum. The mode of finance for the above acquisition and further investment is equity and internal accrual.
DIRECTORS AND KEY MANAGERIAL PERSONNEL (KMP)
Your Company’s Board comprises of 8 (Eight) Directors, of which 5 (Five) Directors are Non-Executive and 3 (Three) Directors are Executive.
a. Appointment / Resignation of Directors:
The Company has re-appointed Mr. Digant Mahesh Parikh (DIN: 00212589) as an Independent Director for a second term of 5 (five) years by passing special resolution through postal ballot and his office shall not be liable to retire by rotation.
The Board of Directors has appointed Ms. Shailaja Vardhan (DIN: 10172764) as an Additional Director in the Category of Independent Non-Executive Director with effect from 30th May, 2023 and her office shall not be liable to retire by rotation.
Ms. Meena Rani Surana (DIN: 08863769) has resigned from the Board as an Independent Director with effect from 30th May, 2023.
b. Retirement of Director by rotation:
In terms of Section 152 of the Companies Act, 2013, Dr. Sunny Sharma (DIN: 02267273) will retire by rotation at the ensuing Annual General Meeting and being eligible for re-appointment, offers himself for re-appointment.
c. Appointment / Resignation of Key Managerial Personnel:
During the year under review, there is no change in the Key Managerial Personnel of the Company.
NUMBER OF MEETINGS OF THE BOARD
During the financial year 2022-23, the Board met 9 (Nine) times on 23.04.2022, 30.05.2022, 08.07.2022, 29.07.2022, 13.08.2022, 10.10.2022, 14.11.2022, 20.01.2023 and 13.02.2023.
POLICY ON DIRECTORS APPOINTMENT AND REMUNERATION
Your Company has in place a policy relating to nomination and remuneration of directors as well as key managerial personnel and other employees formulated by the Nomination and
Remuneration Committee. The Nomination and Remuneration Policy, inter alia, provides for the following:
1. The Committee shall identify and ascertain the integrity, qualification, expertise and experience of the person for appointment as Director in terms of Diversity Policy of the Board and recommend to the Board his / her appointment.
2. For the appointment of KMP (other than Managing / Wholetime Director) or Senior Management, a person should possess adequate qualification, expertise and experience for the position he / she is considered for the appointment. For administrative convenience, the Managing Director is authorised to identify and appoint a suitable person for the position of KMP (other than Managing / Whole-time Director) and Senior Management.
3. The remuneration / compensation / commission, etc., as the case may be, to the Managing / Whole-time Director is determined by the Nomination and Remuneration Committee and recommended to the Board for approval. Such remuneration / compensation / commission, etc., as the case may be, is subject to approval of the shareholders of the Company and is in accordance with the provisions of the Companies Act, 2013 and Rules made thereunder. Remuneration of KMP (other than Managing / Wholetime Director) and Senior Management is decided by the Managing Director based on the standard market practice and prevailing HR policies of the Company.
4. The remuneration / commission / sitting fees, as the case may be, to the Non-Executive / Independent Director, is in accordance with the provisions of the Companies Act, 2013 and the Rules made thereunder for the time being in force or as may be decided by the Committee / Board / shareholders.
5. An Independent Director is not entitled to stock option of the Company.
DISCLOSURE UNDER SECTION 197(14) OF THE COMPANIES ACT, 2013
During the Financial Year 2022-23, Mr. Mark Saldanha, Managing Director of the Company has also received remuneration of H 1,15,66,080.00 from the Company’s wholly owned subsidiary Time-Cap Laboratories Inc.
EVALUATION OF PERFORMANCE OF BOARD, COMMITTEE AND DIRECTORS
Performance evaluation of the Board as a whole, the Committees of Directors and all individual Directors including Independent Directors has been carried out for the year under review in accordance with the criteria framed pursuant to the
provisions of the Companies Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Guidance Notes issued by SEBI.
Performance Evaluation of each individual director including independent director
A questionnaire containing performance evaluation criteria was circulated to each Director including Independent Directors. The Directors filled-up the questionnaire pertaining to other Directors (except for himself/herself) and submitted the same to the Chairman of the Board for review.
The Nomination and Remuneration Committee also carried out performance evaluation of each director of the Company for the year 2022-23. The evaluation of each director was done by all the other directors (other than the director being evaluated) in accordance with the performance criteria suggested by the Committee and applicable SEBI Guidance Note.
Performance Evaluation of the Board and Committees of Directors
The Board reviewed a questionnaire containing performance criteria for the Board and the Committees of Directors. For the evaluation, the Board took into consideration composition of the Board and Committees of Directors, frequency of the meetings, attendance of each directors at the Board and respective Committee Meetings, discharge of key functions and responsibilities prescribed under law, effectiveness of corporate governance practices in the Company, integrity of the Company’s accounting/auditing and financial reporting/control systems, etc.
All the independent directors of your Company also had a separate meeting without the attendance of executive directors and management personnel and reviewed the performance of the Board of Directors as a whole, the Chairman of the Board and the executive non-independent directors during the year 202223. The independent directors have also reviewed the quality, quantity and timeliness of flow of information between the Company management and the directors that was necessary for the directors to effectively and reasonably perform their duties.
The results of the above performance evaluations are satisfactory and adequate and meet the requirement of the Company.
DECLARATION FROM INDEPENDENT DIRECTORS
The Company has received necessary declaration from all the Independent Directors confirming that they meet the criteria of independence as laid down in Section 149(6) of the Companies Act, 2013 read with Schedule IV of the Act and rules made thereunder, as well as Regulations 16(1)(b) of the SEBI Listing regulations and they have registered themselves with the Independent Director’s Database maintained by the Indian
Institute of Corporate Affairs. The Independent Directors also confirmed that they are not aware of any circumstance or situation, which exist or may be reasonably anticipated, that could impair or impact their ability to discharge their duties. In the opinion of the Board, the Independent Directors fulfilled the conditions specified in the above Act and Regulations and are independent of the management.
FAMILIARIZATION PROGRAMME FOR INDEPENDENT DIRECTORS
The Company conducts Familiarization Programme for Independent Directors to enable them to understand their roles, rights and responsibilities and proactively keeps them informed of the activities of the Company, its management and operations and provides an overall industry perspective as well as issues being faced by the industry. Company’s policy on the familiarization program for the independent directors as well as details of familiarization programme imparted during the year is available on the Company’s weblink at http://marksanspharma.com/pdf/familiarisation-programme-for-independent-directors-2022-23.pdf.
COMMITTEES OF THE COMPANY
Currently, the Company has five committees; The Audit Committee, The Nomination and Remuneration Committee, The Stakeholders’ Relationship Committee, The Corporate Social Responsibility Committee and The Risk Management Committee. Details of the composition of these committees are given in the Corporate Governance Report section of this Annual Report.
POLICIES AND CODES
Your Company always strives to promote and follow the highest level of ethical standards in all its business transactions. SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 mandated formulation of certain policies and codes for all listed companies. All the policies and codes adopted by your Company are available on the weblink at http://marksanspharma.com/codes-policies.html. These policies and codes are reviewed periodically by the Board and updated based on need and new compliance requirement. Key policies and codes that have been adopted by the Company are as follows:
|
Name of the Policy and Code with weblink
|
Brief Description
|
|
Code of Conduct for Directors & Employees at http://marksanspharma.com/pdf/Code-of-Conduct.pdf
|
The Code envisages directors and employees of the Company to observe in day to day operations of the Company
|
|
Code of Conduct to Regulate, Monitor and Report Trading in securities at http://marksanspharma.com/pdf/Code-Of-Conduct-Insider-Trading.pdf
|
The Code provides framework for dealing with securities of the Company by directors and employees of the Company
|
|
Policy on Related Party Transactions at http://marksanspharma. com/pdf/Policy-on-materiality-of-related-party-transactions-and-on-dealing-with-related-party-transactions.pdf
|
The Policy regulates all transactions between the Company and its related parties
|
|
Corporate Social Responsibility (CSR) Policy at http://marksanspharma.com/pdf/CSR-Poilcy.pdf
|
The Policy outlines Company’s strategy to bring about a positive impact on society
|
|
Whistle Blower Policy (Vigil Mechanism) at http://marksanspharma.com/pdf/whistle-blower-policy.pdf
|
The Policy provides for directors and employees to report concerns about unethical behavior, actual or suspected fraud or violation of the Company’s codes of conduct and ethics
|
|
Policy for determination of materiality of events or information and disclosures at http://marksanspharma.com/pdf/determining-materiality-for-disclosures.pdf
|
The policy provides for determination of materiality of events or information and disclosures of the same to stock exchanges
|
|
Code of Practice and Procedure for Fair Disclosure of Unpublished Price Sensitive Information at http://marksanspharma.com/pdf/ code-of-fair-disclosure.pdf
|
The Code envisages fair disclosure of events and occurrences that could impact price discovery in the market for the Company’s securities.
|
|
Policy for determining Material Subsidiary at http:// marksanspharma.com/pdf/policy-on-material-subsidiary.pdf
|
The Policy provides criteria when a subsidiary becomes a material subsidiary
|
|
Dividend Distribution Policy at http://marksanspharma.com/pdf/ dividend-distribution-policy.pdf
|
The Policy envisages criteria for distribution of dividend.
|
|
Nomination and Remuneration Policy at http://marksanspharma. com/pdf/nomination-and-remuneration-policy.pdf
|
Policy provides for criteria for appointment and remuneration of Directors and Employees of the Company.
|
DEPOSITS
During the year under review, the Company has not accepted any deposit within the meaning of Section 73 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014 and therefore, there are no deposits which are outstanding as on the date of the Balance Sheet.
LOANS, GUARANTEES OR INVESTMENTS
Details of Loans, Guarantees and Investments covered under the provisions of Section 186 of the Companies Act, 2013 read with the Companies (Meetings of Board and its Powers) Rules, 2014, are given in Note No. 40(d) of the notes to the Standalone Financial Statements of the Company.
RESEARCH AND DEVELOPMENT (R&D)
Your Company is committed to continuously fund its R&D capabilities. One of the Company’s biggest strength lies in vibrant and productive R&D function that has continuously placed your Company ahead through consistent development of niche technology, processes and products. Your Company will continue to invest in R&D to keep pace with the changing global scenario.
Your Company has a Research & Development Centre at Verna, Goa and at Navi Mumbai, Maharashtra to foray into new segments, respond to globally unmet therapeutic needs, enhance the Company’s opportunity responsiveness and file a larger number of ANDAs.
REGULATORY COMPLIANCES
Your Company’s facilities in UK and USA are approved by UK MHRA and US FDA respectively. The Goa facility has also gone through successful GMP audit by US FDA, UK MHRA and Australian TGA Authorities.
CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO
The information on Energy Conservation, Technology Absorption and Foreign Exchange Earnings and Outgo as required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 is annexed to this report as Annexure - A.
INTERNAL FINANCIAL CONTROL SYSTEMS AND THEIR ADEQUACY
Your Company has in place adequate system of internal control and management information systems which covers all financial
and operating functions. These systems are designed in a manner which provides assurance with regard to maintenance of strict accounting control, optimum efficiency in operations and utilization of resources as well as financial reporting, protection of Company’s tangible and intangible assets and compliance with policies, applicable laws, rules and regulations. Your Company has in place a mechanism to identify, assess, monitor and mitigate various risks to key business objectives. The Audit Committee has a process for timely check for compliance with the operating systems, accounting procedures and policies. Major risks identified by the Company are systematically addressed through mitigating action on continuing basis.
INFORMATION TECHNOLOGY
Your Company continues to make required investments in the Information Technology area to cope up with the growing information needs necessary to manage operations efficiently. Your Company has implemented state-of-the-art IT applications in automating the processes in Quality, Manufacturing and R&D. Your Company has also invested significant amount of resources to build IT platform to de-risk manufacturing process and to adopt best practices in the industry. The implementations spread across Lab automation, instrument integration and manufacturing execution systems. Virtually every aspect of your Company’s business operations is carried out through SAP (Systems Applications and Products in Data Processing) Enterprise Resource Planning.
HEALTH, SAFETY & ENVIRONMENT
Your Company is committed to ensure Safety and sound Health of the employees at the work place. Your Company is also committed to strengthen pollution prevention and waste management practices for a safe and healthy environment. The Company’s Plants are in compliance with environmental regulations.
RELATED PARTY TRANSACTIONS
Your Company has not entered into any transaction during the year with any related parties which are not at arm’s length basis.
All Related Party Transactions (with the subsidiaries) that were entered into during the financial year were in the ordinary course of business on arm’s length basis and repetitive in nature. These transactions were placed before the Audit Committee for information and entered in the Register maintained under Section 189 of the Companies Act, 2013. The Audit Committee has granted omnibus (ad hoc) approval for Related Party Transactions as per the provisions and restrictions contained in the policy framed under Regulation 23 of the SEBI (LODR) Regulations, 2015. Company’s Policy on Related Party Transactions is available
on the Company’s weblink at http://marksanspharma.com/ pdf/Policy-on-materiality-of-related-party-transactions-and-on-dealina-with-related-party-transactions.pdf. Particulars of related party transactions entered into during the FY 2022-23 have been disclosed under Note No. 40(c) of the Notes to the Standalone Financial Statement. Details of material transactions with the related parties entered into during the year are disclosed in Form - AOC - 2 annexed to this report as Annexure - B.
WHISTLE BLOWER POLICY/VIGIL MECHANISM
Your Company has in place a Whistle Blower Policy to deal with instance of fraud and mismanagement, if any. Under the policy, an effective vigil mechanism for directors and employees has been established to report their genuine concerns, actual or suspected fraud or violation of the Company’s codes of conduct. The details of establishment of the Whistle-Blower Policy have been disclosed on the Company’s weblink at http://marksanspharma.com/pdf/whistle-blower-policy.pdf.
The said mechanism also provides for adequate safeguards against victimisation of the persons who use such mechanism and makes provision for direct access to the chairperson of the Audit Committee. During the financial year 2022-23, no employee of the Company was denied access to the Audit Committee and there were no instances of any unethical behaviour, actual or suspicious fraud or violation in the Company’s operational policies.
RISK MANAGEMENT SYSTEM
Your Directors are aware of the risks associated with the Company’s business. Your Company makes timely and regular analyses of various risks associated with the Company’s business and takes corrective actions for managing/mitigating the same. Your Company has institutionalized the policy/process for identifying, minimizing and mitigating risks under the supervision of the Risk Management Committee of the Company. The key risks and mitigation measures are also reviewed by the Audit Committee. There is no element of risk which in the opinion of the Board may threaten the existence of the Company.
CORPORATE SOCIAL RESPONSIBILITY
Your company understands its responsibility towards the society, community and environment and committed to spend sensibly to meet its CSR objectives. The report on the CSR activities undertaken by the Company in the format prescribed under the Companies (Corporate Social Responsibility Policy) Amendment Rules, 2021 is given in Annexure - C annexed to this Report.
DISCLOSURE UNDER SEXUAL HARASSMENTOF WOMAN AT WORKPLACE (PREVENTION,PROHIBITION AND REDRESSAL) ACT, 2013
Your Company is fully committed to uphold and maintain dignity of women working in the Company and has zero tolerance towards any actions which may fall under the ambit of sexual harassment at work place. The Company has in place a Prevention of Sexual Harassment Policy in line with the requirements of the Sexual Harassment of Women at the Workplace (Prevention, Prohibition and Redressal) Act, 2013. Internal Complaints Committees have been set up in compliance with provisions relating to the constitution of Internal Complaints Committee under the said Act to redress complaints regarding sexual harassment at Mumbai office, Goa plant and R&D Centre at Navi Mumbai. All employees (permanent, contractual, temporary, trainees) are covered under this policy. During the year under review, the Company has not received any complaints related to sexual harassment at any of the locations and the necessary annual report has been submitted to the competent authority in this regard.
SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS
There are no orders passed by the Regulators/ Courts/ tribunal which would impact the going concern status of the Company and its future operations. During the year under review, securities of the Company were not suspended from trading in the stock exchanges in which they are listed.
CHANGE IN THE NATURE OF BUSINESS
During the year under review, there is no change in the nature of Business of the Company.
MATERIAL CHANGES & COMMITMENT AFFECTING FINANCIAL POSITION OF THE COMPANY
There have been no material changes and commitments, affecting the financial position of the Company between the end of the financial year of the Company to which the financial statements relate and the date of this Report.
CORPORATE GOVERNANCE
Corporate Governance is an ethical business process to create and enhance value of stakeholders and reputation of an organization. Your directors function as trustee of the shareholders and ensure long term economic value for its stakeholders. Pursuant to Schedule V of SEBI (LODR) Regulations, 2015, a detailed report on Corporate Governance and a certificate from the Auditors regarding compliance with the conditions of Corporate Governance is annexed to this report as Annexure - D.
ANNUAL RETURN
In accordance with the requirements of Section 92(3) of the Companies Act, 2013 and Rule 12 of the Companies (Management and Administration) Rules, 2014, the Annual Return in the prescribed Format proposed to be submitted to the Registrar of Companies for the financial year ended 31st March, 2023 is available in the Company’s weblink at http://marksanspharma. com/annual-reports.html.
INSOLVENCY AND BANKRUPTCY CODE 2016
There is no application made nor any proceeding pending under the Insolvency and Bankruptcy Code 2016.
EMPLOYEES
The ratio of the remuneration of each Director to the median employee’s remuneration and other details in terms of Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, is annexed to this report as Annexure - E.
The statement showing particulars of employees as required under Section 197(12) of the Companies Act, 2013 read with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is annexed to this report as Annexure - F.
HUMAN RESOURCES DEVELOPMENT AND INDUSTRIAL RELATIONS
The guiding principle of HR Policy at your Company is that the “Intellectual Capital” and dedication of employees will help the Company emerge as a successful player in this highly competitive scenario.
The recruitment procedure ensures that people with talent and the right skill sets are selected. Nurturing of talent and a Performance Management System (PMS) is in place to ensure that the coordinated efforts of our people lead to achievement of the Business Goals of the company.
Empowerment and a motivational package ensure that employees keep performing at peak levels. The HR Policy is directed towards creating “Ownership of Goals” at each level and synchronizing the efforts of all employees to achieve the company’s quality and business goals.
Development of skills through mentoring and training by our seasoned professionals ensures that the talent pool keeps expanding. The Leadership Role played by our senior professionals helps to keep the next rung of leadership ready to take up the challenges thrown up by the global market.
The management helps the process of decision making by decentralizing and empowering professionals to execute tasks in a speedy manner. The management fosters information sharing and free exchange of ideas. Above all, the sense of ownership and empowerment to take decisions helps the Company to adapt and be ahead of the competition in this rapidly changing global environment.
The industrial relation at all the plant sites of your Company is cordial.
As on 31st March, 2023, the Company’s permanent employee strength is 852 (809 as on 31st March, 2022).
DIRECTORS RESPONSIBILITY STATEMENT
In terms of provisions of Section 134(3)(c) of the Companies Act, 2013, your Directors confirm that:
- in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
- they have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company at the end of the financial year ended 31st March, 2023 and Profit of the Company for the period ended 31st March, 2023;
- proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- the annual accounts have been prepared on a going concern basis;
- proper internal finance controls were in place and that the financial controls were adequate and were operating effectively;
- they have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.
BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT
The Business Responsibility and Sustainability Report for the financial year 2022-23 forms part of this Annual Report as required under Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Annexure - G.
AUDIT & AUDITORS
Statutory Audit:
The Auditors have issued an unmodified opinion on the Financial Statements, both standalone and consolidated for the financial year ended 31st March, 2023. The Auditor’s reports for the financial year 2022-23 do not contain any qualification, reservation or adverse remark.
Secretarial Audit:
Pursuant to the provisions of Section 204 of the Companies Act, 2013, the Board of Directors has appointed M/s Jinesh Dedhia & Associates, Practising Company Secretaries (Membership No. 54731, Certificate of Practice No. 20229) as Secretarial Auditor to undertake Secretarial Audit of the Company for the financial year 2022-23. The report of the Secretarial Auditor is annexed to this report as Annexure - H. There are no qualifications, reservation or adverse remark made by the auditor in their report.
Cost Audit:
The Company has maintained the cost accounts and cost records as specified by the Central Government under subsection (1) of Section 148 of the Companies Act, 2013. However your Company is a 100% export oriented unit and therefore, it is exempted from audit of its cost accounting records.
Reporting of Frauds:
There was no instance of any fraud during the year under review which required the Statutory Auditors to report to the Audit Committee or the Board under Section 143(12) of Act and Rules framed thereunder.
Secretarial Standards
The Company has complied with the applicable Secretarial Standards, i.e. SS-1 and SS-2, relating to ‘Meetings of the Board of Directors’ and ‘General Meetings’, respectively.
APPRECIATION:
The directors place on record their appreciation for the contribution made by the employees at all levels enabling the Company to achieve the performance during the year under review.
The directors also appreciate the valuable co-operation and continued support extended by Company’s Bankers, Medical Professionals, Business Associates and Investors who have put their faith in the Company.
For and on behalf of the Board of Directors of Marksans Pharma Limited
Mark Saldanha
Mumbai Chairman & Managing Director
Dated: 1st August, 2023 DIN: 00020983
|